Study On The Therapeutic Effect Of Multifunctional Mesoporous Silica Loaded With ENO1 Monoclonal Antibody On Cervical Cancer

Objective The study prepared ENO1 monoclonal antibody(ENO1 mAb),which entered the cytoplasm via multifunctional mesoporous silica nanoparticles,and studied the therapeutic effect of ENO1 mAb on cervical cancer in vitro,laying a foundation for targeted metabolic therapy of cervical cancer.Method 1.ENO1 mAb was prepared by in vivo induction method and purified by octanoic-ammonium sulfate method and Protein A column.2.Dendritic mesoporous silica nanoparticle(DMSN)was prepared by oil-water two-phase method,loaded with ENO1 mAb,and connected to hyaluronic acid(HA)by disulfide bond.It was characterized by scanning electron microscopy(SEM),transmission electron microscopy(TEM),dynamic light scattering(DLS),Zeta potential and Fourier infrared spectrum.3.MTT method was used to detect the effect of ENO1 mAb on the proliferation of Hela cells,and cell scratch assay was used to detect the effect of ENO1 mAb on the migration of cervical cancer cells.Results 1.ENO1 mAb was successfully prepared and the purification conditions were optimized.Finally,the optimal purification conditions were obtained by using the binding buffer solution with p H 7.4,0.02 M PB+ 0.15 M Na Cl concentration,p H 3.0 and 0.1M sodium citrate eluent.2.Dendritic mesoporous silica nanoparticles modified with hyaluronic acid were successfully prepared.The particle size was about 100 nm and the pore size was about 10 nm,which all met the experimental requirements.It was found that hyaluronic acid was successfully modified on the surface of dendritic mesoporous silica by Zeta potential and FT-IR,and It has good biocompatibility;3.When the concentrations of DMSN@ENO1 mAb and DMSN-SSHA@ENO1 mAb reached 200μg/ml,the relative proliferation rates of Hela cells were53.13±1.547% and 44.92±0.678%,respectively,showing statistically significant differences compared with the control group.When ENO1 mAb and Hela cells were co-incubated for 12 h,the Hela cell migration rates of free ENO1 mAb and DMSN-SS-HA@ENO1 mAb group were9.765±1.02% and 12.40±0.71%,respectively,showing statistical differences compared with the control group(19.67±1.71%),and 18.14±1.85% in the DMSN@ENO1 mAb group,showing no statistical differences compared with the control group.Conclusion 1.ENO1 mAb was successfully prepared and purified.2.DMSN was successfully prepared and modified with HA,so that ENO1 mAb could enter the cytoplasm with high efficiency.3.Multifunctional mesoporous silica loaded with ENO1 mAb can inhibit the proliferation and migration of cervical cancer cells.